Dyadic International Q2 2023 Earnings Report

Dyadic International EPS Results

• Actual EPS: -$0.07
• Consensus EPS: -$0.05
• Beat/Miss: Missed by -$0.02
• One Year Ago EPS: N/A

Dyadic International Revenue Results

• Actual Revenue: $0.84 million
• Expected Revenue: $1.30 million
• Beat/Miss: Missed by -$460.00 thousand
• YoY Revenue Growth: N/A

Dyadic International Announcement Details

• Quarter: Q2 2023
• Date: 8/9/2023
• Time: N/A

Dyadic International (NASDAQ:DYAI), a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.